NDC 68727-900

Rylaze

Asparaginase Erwinia Chrysanthemi (recombinant)-rywn

Rylaze is a Intramuscular Injection in the Human Prescription Drug category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is Asparaginase.

Product ID68727-900_19a01d9d-35ce-49dc-a2c9-958a1db5f895
NDC68727-900
Product TypeHuman Prescription Drug
Proprietary NameRylaze
Generic NameAsparaginase Erwinia Chrysanthemi (recombinant)-rywn
Dosage FormInjection
Route of AdministrationINTRAMUSCULAR
Marketing Start Date2021-06-30
Marketing CategoryBLA /
Application NumberBLA761179
Labeler NameJazz Pharmaceuticals, Inc.
Substance NameASPARAGINASE
Active Ingredient Strength20 mg/mL
Pharm ClassesAsparaginase [CS], Asparagine-specific Enzyme [EPC]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 68727-900-03

3 VIAL, SINGLE-DOSE in 1 CARTON (68727-900-03) > .5 mL in 1 VIAL, SINGLE-DOSE (68727-900-01)
Marketing Start Date2021-06-30
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Rylaze]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RYLAZE
RYLAZE
88789656 not registered Live/Pending
Jazz Pharmaceuticals Ireland Limited
2020-02-07

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.